Loading clinical trials...

Levetiracetam in the Management of Bipolar Depression | Clinical Trials | Clareo Health

COMPLETEDNA

Levetiracetam in the Management of Bipolar Depression

NCT00566150•Yale University

Summary

A 6-week outpatient, double-blind, placebo-controlled, add-on trial to investigate the effects of levetiracetam on depressive symptoms in bipolar depressed patients.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•DSM-IV diagnosis of bipolar disorder
•Presence of a current major depressive episode on the SCID
•Score of 17 or great on the HDRS
•Capable of giving voluntary written consent

Exclusion Criteria

•Significant current substance dependence/abuse within 3 months preceding the trial
•Active suicidal ideation
•Pregnant/lactating mothers
•Significant medical history

Locations (1)

Yale University School of Medicine

New Haven, Connecticut, United States

Key Dates

Start Date

October 1, 2005

Primary Completion Date

August 1, 2008

Completion Date

August 1, 2008

Last Updated

March 31, 2020

Enrollment

ACTUAL participants

Conditions

Bipolar Depression

Interventions

Levetiracetam

DRUG

Placebo

DRUG

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918

Treatment Resistant DepressionMajor Depressive Episode+5 more

View study

RECRUITINGNA

Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression

NCT06524505

Bipolar Depression

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 31, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Levetiracetam in the Management of Bipolar Depression

Inclusion Criteria

Exclusion Criteria

University of Iowa Interventional Psychiatry Service Patient Registry

Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

HD-tDCS for Adolescent Bipolar Depression Targeting S1

Delivering Electronic Cognitive Behavioural Therapy to Patients With Bipolar Disorder and Residual Depressive Symptoms